Manu Jain

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Harry Heijerman, Edward F. McKone, D.G. Downey et al. · The Lancet · 2019 · 1.3K citations · Full text

Mendelian Disorder, Genetics, Ivacaftor Combination Regimen +2

Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis

Paul A. Reyfman, James M. Walter, Nikita Joshi et al. · American Journal of Respiratory and Critical Care Medicine · 2018 · 1.2K citations · Full text

Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span

Alexander V. Misharin, Luisa Morales‐Nebreda, Paul A. Reyfman et al. · The Journal of Experimental Medicine · 2017 · 1.1K citations · Full text

Acute Lung Injury, Monocyte-derived Alveolar Macrophages, Inflammatory Lung Disease +19

An integrated cell atlas of the lung in health and disease

Lisa Sikkema, Ciro Ramírez-Suástegui, Daniel Strobl et al. · Nature Medicine · 2023 · 656 citations · Full text

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation

John P. Clancy, Steven M. Rowe, Frank J. Accurso et al. · Thorax · 2011 · 493 citations · Full text